Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease

  • H. Baas
  • K. Stecker
  • P. A. Fischer
Full Papers


Despite widespread use in pharmacotherapeutical trials, in the majority of rating scales used in Parkinson's disease (PD) validity, reliability and appropriate use have never been confirmed by statistical data. For this reason 350 unselected PD-pats. were investigated by an extensive standardized test-battery including registration of basis data, Columbia University Rating Scale (CURS), scale for assessment of functional disability (ADL), SCAG-scale, Hoehn & Jahr-scale (HY), mod. Webster step second-test (WSST), Purduepegboard, questionnaire for subjective complaints (SC), WDG, LPS1/2, 3/4, 6, 7, 10, clinical assessment of dementia, v. Zerssen-scale and orthostatic hypotension (60° tilt up). For CURS, SCAG and ADL instrumental reliability was calculated by Cronbach's alpha. For CURS, SCAG, ADL and the total data of complete test battery (CTB) principal component analysis (PCA) was performed for data reduction. CURS, SCAG and ADL showed high internal consistency (alpha ∼≥0.9). For CURS 5 factors accounting for 66% total variance could be extracted by PCA. They represent gait, rigidity, tremor, right/left dexterity (eigenvalues >1). For SCAG 3 factors (61% of total variance) representing dementia, depression and change of personality were extracted. For ADL 3 factors (67% of total variance) could be extracted, representing overall functional disability, handwriting and disablity by pain. PCA of the CTB identified 8 interpretable factors (66% of total variance) characterizing at least partially the clinical profile of PD: 1. motor disability (assessment by rating-scales) 2. dementia, 3. motor-disability (assessment by apparative measurements), 4. depression, 5. orthostatic hypotension, 6. WDG, 7. tremor and 8. pain. Our data confirm the suitability of the investigated scales and give a rational base for their appropriate use in a sense of data reduction and economical evaluation.


Parkinson-syndrome clinical documentation statistical analysis rating scales statistical evaluation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alba A, Trainor FS, Ritter W, Dacso MM (1968) A clinical disability rating for Parkinson patients. J Chron Dis 21: 507–522CrossRefPubMedGoogle Scholar
  2. Baas H, Fischer PA (1984) Salbengesicht. Zentrale Dyregulation der Talgsekretion beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Vegetativstörungen beim Parkinson-Syndrom. Editiones Roche, Basel/Grenzbach, S 221–234Google Scholar
  3. Baas H, Fischer PA (1986) Fluktuationen der Beweglichkeit beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Spätsyndrome der Parkinson-Krankheit. Editiones Roche, Basel/Grenzach, S 213–233Google Scholar
  4. Birkmayer W, Neumayer E (1972) Die moderne medikamentöse Behandlung des Parkinsonismus. Z Neurol 202: 257–280CrossRefPubMedGoogle Scholar
  5. Briebach T, Baa H, Fischer PA (1990) Orthostatische Regulationsstörung beim Parkinson-Syndrom. Nervenarzt 61: 491–494PubMedGoogle Scholar
  6. Brown RG, McCarthy B, Jahanshahi M, Marsden CD (1989) Accuracy of self reported disability in patients with parkinsonism. Arch Neurol 46: 955–959PubMedGoogle Scholar
  7. Canter GJ, de la Torre R, Mier M (1961) A method for evaluating disability in patients with Parkinson's disease. Nerv Ment Dis 133: 143–147Google Scholar
  8. Cassell K, Shaw K, Stern G (1973) A computerized tracking technique for the assessment of parkinsonian motor disabilities. Brain 96: 815–826PubMedGoogle Scholar
  9. Cleeves L, Findley LJ, Gresty M (1986) Assessment of rest tremor in Parkinson's disease. Adv Neurol 45: 349–352Google Scholar
  10. Diamond SG, Markham CH (1983) Evaluating the evaluations: or how to weight the scale of parkinsonian disability. Neurology 33: 1098–1099PubMedGoogle Scholar
  11. Duvoisin RC (1970) The evaluation of extrapyramidal disease. In: Ajuriaguerra J (ed) Monoamines, noyeaux gris centraux et syndrome de Parkinson. Masson, Paris, pp 313–325Google Scholar
  12. Fahn S, Elton RL, UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. Macmillian Health Care Information, New York, pp 153–164Google Scholar
  13. Fischer PA (1986) Longterm course in Parkinson's syndrome and cerebral polypathy(Parkinson plus). Adv Neurol 45: 235–238Google Scholar
  14. Forrest M, Andersen B (1986) Ordinal scale and statistics in medical research. Br Med J 292: 537–538Google Scholar
  15. Gaitz CM, Varner RV, Overall JE (1977) Pharmacotherapy for organic brain syndrome in late life. Arch Gen Psychiatry 34: 839–845PubMedGoogle Scholar
  16. Gerstenbrand F, Klingler D, Poewe W, Schnaberth G (1986) Präsentation des Dokumentationsbogens für Parkinsonkranke der Österreichischen Parkinsongesellschaft. In: Schnaberth G, Auff E (Hrsg) Das Parkinson-Syndrom. Editiones Roche, WienGoogle Scholar
  17. Godwin-Austen RB, Tomlinson EB, Frears CC, Kok HWL (1969) Effects of L-Dopa in Parkinson's disease. Lancet ii: 165–168CrossRefGoogle Scholar
  18. Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49: 381–389PubMedGoogle Scholar
  19. Hamot HB, Patin RJ, Singer MJ (1984) Factur structure of the Sandoz Clinical Assessment Geriatric Scale (SCAG). Psychopharmacol Bull 20: 142–150PubMedGoogle Scholar
  20. Hely M, Morris JGL, Wilson A, Fahey P, O'Sullivan DJ, Williamson PM (1990) An evaluation of the Columbia Scale. In: Agnoli A (ed) European Conference on Parkinson's Disease and Extrapyramidal Disorders. John Libbey, Rome London Paris New York, p 136 (Abstract)Google Scholar
  21. Hoehn MM, Yahr MD (1967) Parkinsonism: onset progression and mortality. Neurology 17: 427–442PubMedGoogle Scholar
  22. Horn W (1983) Leistungsprüfsystem (LPS) Handanweisung, 2. Aufl. Hogrefe, GöttingenGoogle Scholar
  23. Jankovic J, Frost JD (1980) Quantitative assessment of parkinsonism and essential tremor: clinical application of triaxial accelerometry. Neurology 30: 393Google Scholar
  24. Kartzinel R, Calne DB (1976) Studies with bromocriptine. Part 1. On-off phenomena. Neurology 26: 508–510PubMedGoogle Scholar
  25. Kennard C, Munro AJ, Park DM (1984) The reliability of clinical assessment of Parkinson's disease. J Neurol Neurosurg Psychiatry 47: 322–323PubMedGoogle Scholar
  26. Korten JJ (1977) Correlations in 80 patients with Parkinson's disease. In: Lakke JPWF, Korf J, Wesseling H (eds) Parkinson's disease. Concepts and prospects. Excerpta Medica, Amsterdam, pp 101–110Google Scholar
  27. Lakke JPWF (1981) Classification of extrapyramidal disorders. J Neurol Sci 51: 311–327CrossRefPubMedGoogle Scholar
  28. Lang AET, Fahn S (1989) Assessment of Parkinson's disease. In: Munsat T (ed) Quantification of neurological deficits. Butterworth, Boston, pp 285–309Google Scholar
  29. Larsen TA, LeWitt PA, Calne DB (1983) Theoretical and practical issues in assessment of deficits and therapy in parkinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 363–373Google Scholar
  30. Larsen TA, Calne S, Calne DB (1984) Assessment of Parkinson's disease. Clin Neuropharmacol 7: 165–169PubMedGoogle Scholar
  31. Liebermann A, Dziatolowski M, Gopinathan G, Kopersmith M, Neophytides A, Korein J (1980) Evaluation of Parkinson's disease. In: Goldstein M (ed) Ergot compounds and brain function. Neuroendocrine and neuropsychiatric aspects. Raven Press, New York, pp 277–286Google Scholar
  32. Markham CH, Diamond SG (1981) Evidence to support early levodopa therapy in Parkinson's disease. Neurology 31: 125–131PubMedGoogle Scholar
  33. Marsden CD, Schachter M (1981) Assessment of extrapyramidal disorders. Br J Clin Pharmacol 11: 129–151PubMedGoogle Scholar
  34. Martinez-Martin P, Bermejo-Parejy F (1988) Rating scales in Parkinson's disease. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders. Urban & Schwarzenberg, Baltimore MunichGoogle Scholar
  35. Mc Dowell F, Lee JE, Swift T, Sweet RD, Ogsbury JS, Tessler JT (1970) Treatment of Parkinson's syndrome with dihydroxyphenylalanine (levodopa). Ann Intern Med 72: 29–35PubMedGoogle Scholar
  36. Montgomery GK (1984) PD and Columbia Scale. Neurology 34: 557–558Google Scholar
  37. Montgomery GK, Reynolds NC, Warren RM (1985) Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 8: 83–92PubMedGoogle Scholar
  38. Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970a) Controlled trial of amantadine hydrichloride in Parkinson's disease. Lancet i: 259–262CrossRefGoogle Scholar
  39. Parkes JD, Zilkha KJ, Marsden CD, Baxter RCH, Knill-Jones RP (1970b) Amantadine dosage in treatment of Parkinson's disease. Lancet i: 1130–1133CrossRefGoogle Scholar
  40. Petrinovich L, Hardyck C (1964) Behavioural changes in Parkinson patients. A factor analytical study. J Chron Dis 17: 225–233CrossRefGoogle Scholar
  41. Potvin AR, Tourtelotte WW (1975) The neurological examination: advancements in its quantification. Arch Phys Med Rehabil 56: 425–437PubMedGoogle Scholar
  42. Schwab RS, England RC (1969) Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC (eds) 3rd Symposium on Parkinson's Disease. E. S. Livingstone, EdinburghGoogle Scholar
  43. Shader RI, Harmatz JS, Salzman C (1974) A new scale for clinical assessment on geriatric populations: SANDOZ Clinical Assessment Geriatric (SCAG). J Am Geriatr Soc 22: 107–113PubMedGoogle Scholar
  44. Taylor AE, Saint-Cyr JA, Lang AE (1986) Frontal lobe dysfunction in Parkinson's disease: the cortical focus of neostriatal outflow. Brain 109: 845–883PubMedGoogle Scholar
  45. Teravainen H, Calne DB (1980) Quantitative assessment of Parkinsonian deficits. In: Rinne UK, Klinger M, Stamm G (eds) Parkinson's disease-current progress, problems and management. Elsevier, Amsterdam, pp 145–164Google Scholar
  46. Tiffin J (1979) Purdue pegboard. Examiner manual. Lafayette Instruments Company, Reorder Nr. 7-435. Lafayette 2Google Scholar
  47. Velasco F, Velasco M (1973) A quantitative evaluation of the effects of L-Dopa on Parkinson's disease. Neuropharmacology 12: 89–99CrossRefPubMedGoogle Scholar
  48. Ward CD, Sane JN, Dambrosia JM (1983) Methods for evaluating treatment in Parkinson's disease. In Fahn S, Calne DB, Shoulson I (eds) Advances in neurology, vol 37. Raven Press, New York, pp 1–7Google Scholar
  49. Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treat 5: 257–282PubMedGoogle Scholar
  50. Wiener Determinationsgerät. Schuhfried Ltd, Mödling, AustriaGoogle Scholar
  51. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21: 343–354PubMedGoogle Scholar
  52. Zerssen v D, Koeller DM, Rey ER (1970) Die Befindlichkeits-Skala. Ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneimittelforschung/Drug Res 20: 915–918Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • H. Baas
    • 1
  • K. Stecker
    • 1
  • P. A. Fischer
    • 1
  1. 1.Department of NeurologyUniversity of Frankfurt/MainFrankfurt/MainFederal Republic of Germany

Personalised recommendations